Response to furmonertinib in a patient with non-small cell lung cancer harboring HER2 exon 21 insertion mutation: a case report

Chunxiao Ni, Ling Zhang, Xin Yu, Yu Pang, Jiaju XuFrontiers in Oncology 2024 · DOI

TL;DR

This case report details the first instance of a patient with non-small cell lung cancer (NSCLC) harboring rare HER2 exon 21 insertion mutations (T8962A and L869R) showing a positive response to furmonertinib. This suggests furmonertinib could be a promising, cost-effective treatment option for a specific subset of NSCLC patients with these mutations, warranting further clinical investigation.

What Problem Does This Paper Address?

Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths worldwide. While targeted therapies have revolutionized treatment, they are often specific to certain genetic mutations. The human epidermal growth factor receptor 2 (HER2) gene is a known driver in some cancers, including a small percentage of NSCLCs. However, HER2 alterations in NSCLC are complex, with mutations in different exons and varying types (amplification, insertion, etc.). Specifically, HER2 exon 21 insertion mutations are rare, and their response to existing therapies is not well-understood. Current treatment guidelines and available targeted therapies for HER2-mutant NSCLC, particularly for these uncommon exon 21 insertions, are limited, leaving a gap in effective and accessible treatment options. This paper addresses the need for understanding treatment efficacy in patients with these rare HER2 mutations.

Methods

This paper is a case report, meaning it describes the clinical course of a single patient. The methods employed are standard clinical practices for diagnosing and treating advanced NSCLC:

  • Diagnosis: Computed tomography (CT) scans for imaging, biopsy for tissue analysis, and hematoxylin and eosin (H&E) staining for histological examination.
  • Genetic Profiling: Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) was used to identify specific genetic mutations, including the HER2 exon 21 insertion mutations.
  • Treatment: The patient received various lines of treatment, including:
  • Systemic chemotherapy (bevacizumab, pemetrexed, carboplatin, abraxane, nedaplatin, gemcitabine, cisplatin).
  • Targeted therapy (anlotinib, carrelizumab, furmonertinib, pyrrotinib).
  • Radiotherapy for brain metastases.
  • Monitoring: Tumor markers and serial CT scans were used to assess treatment response and disease progression.

The novelty lies in the application of furmonertinib, an EGFR TKI, to a patient with HER2 mutations, which is not its primary intended target based on current understanding.

Datasets

Not discussed in the paper. The study focuses on a single patient's clinical data.

Key Insights and Ideas

  • Furmonertinib's Potential Beyond EGFR: The most significant insight is that furmonertinib, a third-generation EGFR TKI, demonstrated efficacy in a patient with HER2 exon 21 insertion mutations. This challenges the conventional understanding of targeted therapy specificity and suggests potential off-target or shared pathway activity.
  • Rarity of HER2 Exon 21 Mutations: The paper highlights that HER2 exon 21 mutations are uncommon in NSCLC, making it difficult to gather data and establish treatment protocols for these patients.
  • Economic Considerations in Treatment Choice: The patient opted against trastuzumab deruxtecan (T-DXd) due to its high cost, underscoring the importance of finding more economical treatment options for rare mutations. This makes furmonertinib's potential affordability a crucial factor.
  • Complex Treatment History: The patient's journey involved multiple lines of therapy, including chemotherapy and other targeted agents, none of which provided sustained benefit before furmonertinib. This emphasizes the refractory nature of the disease in this case.

Key Results

  • The patient, diagnosed with stage IV lung adenocarcinoma, had a history of failed multiple lines of treatment.
  • Comprehensive genomic profiling revealed two rare HER2 exon 21 insertion mutations: T8962A and L869R.
  • Initial treatment with furmonertinib (80 mg once daily) led to prominent regression of primary lung tumors and lung-to-lung metastases within one month, and complete relief of cough symptoms and regression of brain metastases within two months.
  • The patient achieved 11 months of progression-free survival (PFS) with furmonertinib.
  • A subsequent increase in furmonertinib dosage (160 mg once daily) showed further regression of lung metastases.
  • After progression, a brief treatment with pyrrotinib was ineffective.
  • Re-initiation of furmonertinib in October 2023 resulted in partial remission by November 2023.
  • No significant treatment-related side effects were reported during furmonertinib treatment.
  • The patient ultimately succumbed to hypoproteinemia and severe pneumonia in December 2023.

Limitations and Future Work

  • Single Case Report: The most significant limitation is that this is a single case report. The findings cannot be generalized to all patients with HER2 exon 21 insertion mutations.
  • Mechanism of Action: The exact mechanism by which furmonertinib exerts its effect on HER2 mutations is not fully elucidated and requires further investigation.
  • Future Work: The authors strongly advocate for further studies, particularly prospective clinical trials, to confirm the efficacy and safety of furmonertinib in NSCLC patients with HER2 T8962A and L869R mutations. This would lay the groundwork for developing optimized therapeutic regimens for patients with uncommon driver gene mutations.

Summary updated

Abstract

Furmonertinib may be effective for NSCLC patients with HER2 T8962A and L869R mutations and further studies are needed to confirm these results in prospective clinical trials.
BibTeX
@inproceedings{ni2024response,
  author = {Chunxiao Ni and Ling Zhang and Xin Yu and Yu Pang and Jiaju Xu},
  title = {{Response to furmonertinib in a patient with non-small cell lung cancer harboring HER2 exon 21 insertion mutation: a case report}},
  booktitle = {Frontiers in Oncology},
  year = {2024},
  doi = {10.3389/fonc.2024.1440379},
}
Figure